You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,214,775

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,214,775

Title:	Method of modulating the activity of functional immune molecules
Abstract:	The invention relates to a method for controlling the activity of an immunologically functional molecules, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having promoted activity.
Inventor(s):	Hanai; Nobuo (Machida, JP), Nakamura; Kazuyasu (Machida, JP), Hosaka; Emi (Machida, JP), Yamasaki; Motoo (Machida, JP), Uchida; Kazuhisa (Machida, JP), Shinkawa; Toyohide (Machida, JP), Imabeppu; Susumu (Ube, JP), Kanda; Yutaka (Machida, JP), Yamane; Naoko (Machida, JP), Anazawa; Hideharu (Tokyo, JP)
Assignee:	Kyowa Hakko Kogyo Co., Ltd. (Tokyo, JP)
Application Number:	11/126,176
Patent Claims:	1. An antibody composition comprising antibody molecules, wherein 100% of the antibody molecules comprising a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region through N-acetylglucosamine of the reducing terminal of the sugar chains do not contain sugar chains with a fucose bound to the N-acetylglucosamines. 2. The antibody composition according to claim 1 wherein the antibody molecule is a molecule selected from the group consisting of (a), (b) and (c): (a) a human antibody; (b) a humanized antibody; (c) an antibody fragment. 3. The antibody composition according to claim 1, wherein the antibody molecule belongs to an IgG class. 4. The antibody composition according to claim 1, wherein said antibody molecule binds to an antigen associated with cancer. 5. The antibody composition according to claim 4, wherein said antibody molecule binds to a CD20 antigen. 6. The antibody composition according to claim 1, wherein said antibody molecule is, except for the lack of fucose bound to the N-acetylglucosamines, rituximab. 7. A composition comprising the antibody composition according claim 1 and a carrier.

Details for Patent 7,214,775

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2019-04-09
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2019-04-09
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2019-04-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.